$LINK

Interlink Electronics Eyes $50M Revenue as Transformative Acquisition Nears

Interlink Electronics (LINK) anticipates reaching $50M in revenue this year, driven by a pending acquisition of a company with $33M in annual revenue. The acquisition, expected to close in 60-90 days, is seen as transformative, bringing the company closer to its $100M revenue goal. Interlink focuses on sensors for AI, healthcare, and robotics, differentiating itself with proprietary algorithms and software.

Original reporting
Published Aug 20, 2026, 12:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 12:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Interlink Electronics Eyes $50M Revenue as Transformative Acquisition Nears — source image
Decision brief

The 30-second read

$LINKBullishMed
01

Why it matters

The announced acquisition is the first public disclosure of a transformative transaction for the company, providing new growth visibility.

02

Market read

The deal could materially increase revenue and attract growth‑oriented investors to the micro‑cap space.

03

What to watch

Potential financing constraints and limited public float could affect liquidity.

Relevance 7/10Novelty 7/10Timing: within the next 60‑90 days as the deal is expected to close

Background

Interlink Electronics (NASDAQ:LINK) is a small-cap sensor and printed‑electronics company targeting AI, robotics, and healthcare markets.

Company-level read

Ticker impact

$LINKBullishMedium confidence
Context

Interlink Electronics disclosed a pending $33M revenue acquisition that could lift its FY revenue to $50M, a transformative deal for the microcap.

Expected impact

Upside pressure as investors price in higher revenue and growth prospects.

Evidence & confidence

Deal size is material for a $12M base revenue company; integration risk is mitigated by retaining teams.

Market effects

Strengthens the niche printed‑electronics and sensor sector with AI‑related applications.

May boost investor interest in U.S. micro‑cap technology stocks.

Limited to niche sensor market; no broad macro effect.

Counterpoint

If integration costs exceed expectations, the deal could dilute earnings and pressure the stock.

Key entities

  • Interlink Electronics

    NASDAQ‑listed sensor and printed‑electronics firm.

Related articles

$LINKMed

INTERLINK ELECTRONICS INC (LINK): Results of Operations and Financial Condition

INTERLINK ELECTRONICS INC (LINK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2620504d2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Interlink Electronics Reports Second Quarter 2026 Results Interlink reports a strong quarter, with increased revenues and a return to profitability FREMONT, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) – Interlink Electronics,

$XRPMed

Key Crypto Updates

Hyperliquid said its RWA open interest hit a new all-time high of $3B. Securitize launched on TRON with Hamilton Lane’s Credit Fund. Ethena partnered with Coinbase to expand on-chain finance and savings. Ripple expanded RLUSD to Türkiye via BiLira. Coinbase invested in ProShares’ IQMM; MoneyGram launched MGUSD on Stellar; MoonPay partnered with Franklin Templeton.

$LINKMedAI 9/10

Crypto Market Recap: Chainlink Gains $4B in Migrations; Worldcoin Rallies on OpenAI IPO Hype; SEC Blocks Prediction Market ETFs; and More (May 17–23, 2026)

Crypto markets were mixed May 17–23, 2026. Bitcoin fell to about $77,200 as spot ETFs reportedly shed $1.4B over five days, with $70K cited as a key level. Chainlink saw $4B in CCIP migrations in two weeks. The SEC sought public input before event-contract prediction market ETFs. Worldcoin rose on OpenAI IPO hype; Polymarket reported a $600K internal-wallet breach.

$LLYMed

Alzecure completes transaction with Lilly

AlzeCure Pharma received a $10M upfront payment from Eli Lilly for the Alzheimer’s project Alzstatin, including drug candidate ACD680. The deal includes potential milestone payments and royalties, with a total value exceeding $1B. Lilly gains global rights to Alzstatin. AlzeCure's CEO noted the payment strengthens their financial position and they will continue work in Alzheimer’s and pain projects.

$WBSHighAI 9/10

WEBSTER FINANCIAL CORP (WBS): Completion of Acquisition or Disposition of Assets

WEBSTER FINANCIAL CORP (WBS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. 8-K WEBSTER FINANCIAL CORP false 0000801337 --12-31 0000801337 2026-08-20 2026-08-20 0000801337 us-gaap:CommonStockMember 2026-08-20 2026-08-20 0000801337 us-gaap:SeriesFPreferredStockMember 2026-08-20 2026-08-20 0000801337 us-gaap:SeriesGPreferredStockMember 2026-08-20 2026-08-2

Interlink Electronics Eyes $50M Revenue as Transformative Acquisition Nears — alphai